- Home
- RNAZ vs APLM Comparison
RNAZ vs APLM Comparison
Compare RNAZ & APLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNAZ
- APLM
- Stock Information
- Founded
- RNAZ 2016
- APLM 2016
- Country
- RNAZ United States
- APLM United States
- Employees
- RNAZ N/A
- APLM N/A
- Industry
- RNAZ Biotechnology: Pharmaceutical Preparations
- APLM Blank Checks
- Sector
- RNAZ Health Care
- APLM Finance
- Exchange
- RNAZ Nasdaq
- APLM Nasdaq
- Market Cap
- RNAZ 6.1M
- APLM 6.9M
- IPO Year
- RNAZ 2021
- APLM N/A
- Fundamental
- Price
- RNAZ $7.97
- APLM $6.41
- Analyst Decision
- RNAZ Strong Buy
- APLM
- Analyst Count
- RNAZ 1
- APLM 0
- Target Price
- RNAZ $280.00
- APLM N/A
- AVG Volume (30 Days)
- RNAZ 32.8K
- APLM 4.6K
- Earning Date
- RNAZ 08-13-2025
- APLM 08-13-2025
- Dividend Yield
- RNAZ N/A
- APLM N/A
- EPS Growth
- RNAZ N/A
- APLM N/A
- EPS
- RNAZ N/A
- APLM N/A
- Revenue
- RNAZ N/A
- APLM $198,000.00
- Revenue This Year
- RNAZ N/A
- APLM $415.15
- Revenue Next Year
- RNAZ N/A
- APLM N/A
- P/E Ratio
- RNAZ N/A
- APLM N/A
- Revenue Growth
- RNAZ N/A
- APLM N/A
- 52 Week Low
- RNAZ $6.15
- APLM $4.47
- 52 Week High
- RNAZ $970.20
- APLM $35.98
- Technical
- Relative Strength Index (RSI)
- RNAZ 47.04
- APLM 51.61
- Support Level
- RNAZ $7.32
- APLM $5.34
- Resistance Level
- RNAZ $8.48
- APLM $6.70
- Average True Range (ATR)
- RNAZ 0.58
- APLM 0.52
- MACD
- RNAZ 0.41
- APLM -0.03
- Stochastic Oscillator
- RNAZ 70.77
- APLM 67.65
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.
About APLM Apollomics Inc.
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.